Uma Singh1, Neetu Ahirwar1, Anju Kumari Rani2, Nisha Singh1, Pushplata Sankhwar1, Sabuhi Qureshi1. 1. Department of Obstetrics & Gynecology, CSM Medical University, Lucknow, 226003 UP India. 2. Department of Obstetrics & Gynecology, CSM Medical University, Lucknow, 226003 UP India ; Type IV/83, SGPGIMS, Raibareily Road, Lucknow, 226014 UP India.
Abstract
OBJECTIVE: A prospective cohort study in a teaching hospital to assess the efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced carcinoma cervix. METHOD: Neoadjuvant chemotherapy in the form of cisplatin 75 mg/m(2) and paclitaxel 135 mg/m(2) on day 1 and repeated at 14 days' interval for up to a maximum of three courses. RESULTS: Neoadjuvant chemotherapy in cervical cancer was effective in the downstaging of the disease. Downstaging was observed in 19.23 % of patients after two cycles and in 50 % of patients after three cycle of NACT. Operability increases to 33.3 and 38.4 % after two and three cycles of NACT, respectively. Complete pathological response was observed in 37.5 % of patients after NACT. No significant adverse effect in the feasibility of surgery was observed. CONCLUSION: The present study showed that neoadjuvant chemotherapy was an effective and well-tolerated mode of therapy with significantly less morbidity and mortality.
OBJECTIVE: A prospective cohort study in a teaching hospital to assess the efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced carcinoma cervix. METHOD: Neoadjuvant chemotherapy in the form of cisplatin 75 mg/m(2) and paclitaxel 135 mg/m(2) on day 1 and repeated at 14 days' interval for up to a maximum of three courses. RESULTS: Neoadjuvant chemotherapy in cervical cancer was effective in the downstaging of the disease. Downstaging was observed in 19.23 % of patients after two cycles and in 50 % of patients after three cycle of NACT. Operability increases to 33.3 and 38.4 % after two and three cycles of NACT, respectively. Complete pathological response was observed in 37.5 % of patients after NACT. No significant adverse effect in the feasibility of surgery was observed. CONCLUSION: The present study showed that neoadjuvant chemotherapy was an effective and well-tolerated mode of therapy with significantly less morbidity and mortality.
Authors: Antonio González-Martín; Lucía González-Cortijo; Natalia Carballo; Juan F Garcia; Fernando Lapuente; Alejandro Rojo; Luis M Chiva Journal: Gynecol Oncol Date: 2008-06-30 Impact factor: 5.482
Authors: T Toita; K Sakumoto; M Higashi; K Ogawa; Y Kakinohana; S Shinzato; H Moromizato; K Kanazawa; S Sawada Journal: Gynecol Oncol Date: 1997-06 Impact factor: 5.482
Authors: Myrna Candelaria; José Chanona-Vilchis; Lucely Cetina; Diana Flores-Estrada; Carlos López-Graniel; Aaron González-Enciso; David Cantú; Adela Poitevin; Lesbia Rivera; Jose Hinojosa; Jaime de la Garza; Alfonso Dueñas-Gonzalez Journal: Int Semin Surg Oncol Date: 2006-02-03